Skip to content
  • PAD
    • DETOUR System
    • DETOUR System Reimbursement
    • DETOUR Professional Education
    • For PAD Patients
    • Find a Doctor
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
    • Clinical Evidence
    • Procedural Training
  • IFU’s
  • About Us
    • About Us
    • News
    • The Team
    • Careers
      • Internal Applicant Portal
      • External Applicant Portal
    • Investigator Initiated
      Research
    • Contact Us
  • PAD
    • DETOUR System
    • DETOUR System Reimbursement
    • DETOUR Professional Education
    • For PAD Patients
    • Find a Doctor
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
    • Clinical Evidence
    • Procedural Training
  • IFU’s
  • About Us
    • About Us
    • News
    • The Team
    • Careers
      • Internal Applicant Portal
      • External Applicant Portal
    • Investigator Initiated
      Research
    • Contact Us
Back to News
  • February 3, 2016

Endologix LLC and TriVascular Technologies, Inc. Complete Merger

PrevPreviousEndologix AFX(R) Endovascular AAA System Receives Shonin Approval for Marketing in Japan
NextEndologix Announces First U.S. Commercial Implant of AFX®2 Bifurcated Endograft SystemNext
FIND IFU HERE
Youtube Linkedin Twitter
Compliance
Privacy Policy
Safety Information
Anti-Trafficking/Modern Slavery
Carbon Reduction Plan UK
Cookie Policy
Terms & Conditions
Patents

© 2026 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.